We propose to test whether H1 and H2 clustering can distinguish patients responsive or resistant to the combination therapy with immunotherapy in a prospective clinical study. |
Principal Investigator
Sukeshi Arora
Regulatory Point of Contact
Frances Crawford
210-450-5037
crawfordf1@uthscsa.edu
Regulatory Point of Contact
Myrna Montenegro
210-450-5954
montenegro@uthscsa.edu
Regulatory Point of Contact
Kathleen Rodriguez
210-450-1365
rodriguezk3@uthscsa.edu
Regulatory Point of Contact
Benjamin Schleif
210-450-1366
schleifb@uthscsa.edu
Regulatory Point of Contact
Morgan Seekatz
210-450-1133
seekatz@uthscsa.edu
1. Patients with HCC who are not candidates for curative or locoregional treatments .
2. Patients who are candidates to receive first-line immunotherapy-based regimens (i.e., atezolizumab/bevacizumab)
3. ECOG performance status 0-2
4. Patients who will have baseline biopsy for HCC and background liver biopsy per SOC
1. Prior systemic therapy for HCC
2. Any contraindication to immunotherapy
a) Prior transplant
b) Uncontrolled autoimmune diseases (i.e., autoimmune hepatitis)
3. Prior anti-PD-L1, anti-PD1, or anti-CTLA4 antibody (or another checkpoint inhibitor)